Jonas Frick

Part of NTG Nordic Transport Group A/S, A. Carlsson Research AB develops and discovers new pharmacological treatment principles for psychiatric and neurological disorders. The company is based in Gothenburg, Sweden. The CEO of the Swedish company is Arvid M. Carlsson. A. Carlsson Research was acquired by NTG Nordic Transport Group A/S on October 23, 2006 for $121.91 million.

Alder AB is an Independent Private Equity/Venture Capital firm founded in 2010 by Dag Lagesson Broman. Alder AB is headquartered in Stockholm.

Nordic Water Products AB operates as a holding company with interest in providing equipment and systems for water and wastewater treatment to process industries and public utilities. Its products include continuous sand filters, sludge scrapers, surface skimmers, flocculators, sludge discharge equipment, fine screens, wash presses, screenings treatment, grit treatment, sludge treatment, lamella separators, and conveyor systems. The company was founded in 1962 and is headquartered in Vastra Frolunda, Sweden.

AB Inventech A/S provides automation solutions for surface treatment processes such as sand blasting, grit blasting, metallizing, paint robot, and dry lube application. The company is based in Ikast, Denmark. The Danish company also has expertise in handling composite materials like prepreg, dry glass fiber, carbon fiber, and carbon pultrusion. The company was founded in 1989 by Arne Just Beck, and the CEO is Niels Kirkegaard. AB Inventech was acquired by Alder AB on December 17, 2021.

Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland.

Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase.

SLS Invest AB (SLS Invest) is a venture capital firm wholly-owned by Sjätte AP-fonden. The firm was established in 2007 and is headquartered in Stockholm, Sweden, with a branch office in Copenhagen, Denmark.